Press Releases

Supplementary proposals of the Nomination Committee for the 2017 Annual General Meeting

For the AGM on September 25, 2017, the Board of Oasmia Pharmaceutical AB has been informed by the company's Nomination Committee of the following. The Nomination Committee proposes that the Board t...

Notification from Oasmia Pharmaceutical AB

Uppsala, Sweden, September 11, 2017 – Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, hereby issues a notification regarding t...

Oasmia Pharmaceutical AB (publ)

Interim report for the period May – July 2017

Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)

Oasmia Pharmaceutical AB (publ) (”Oasmia” or ”Company” or “Group”) has, as has been previously announced, carried out a rights issue. The main part of the shares in the rights issue have b...

NOTICE OF ANNUAL GENERAL MEETING IN OASMIA PHARMACEUTICAL AB

THE SHAREHOLDERS OF OASMIA PHARMACEUTICAL AB ARE HEREBY GIVEN NOTICE OF THE ANNUAL GENERAL MEETING ON 25 SEPTEMBER 2017, AT 10.00 A.M., AT THE OFFICES OF THE COMPANY, VALLONGATAN 1, 752 28 UPPSALA. TH...

Oasmia Pharmaceutical receives market approval for its Anti-Cancer Drug Doxophos® in Russia

Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, announced today that it has received marketing approval of Doxophos in Russia, a...

Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)

Oasmia Pharmaceutical AB (publ) (”Oasmia” or ”Company” or “Group”) has, as has been previously announced, carried out a rights issue. Approximately half of the shares in the rights issue h...

Oasmia Pharmaceutical AB (publ) announces result of the rights issue

The subscription period for Oasmia Pharmaceutical AB’s (publ) (“Oasmia” or the “Company”) rights issue ended on July 5, 2017. The result of the rights issue shows that 23,517,699 shares, rep...

The Oasmia Pharmaceutical Annual Report is now published

The Oasmia Annual Report for the fiscal year 2016/2017 is now available at the company website www.oasmia.com.

Issuance of warrants in Oasmia Pharmaceutical AB (publ)

Oasmia Pharmaceutical AB (publ) (the ”Company”) resolved, at the Extraordinary General Meeting of the Company on 2 June 2017, to establish two warrant programmes, series 2017:1 and series 2017:2, ...